Advanced Drug Delivery Reviews

Article	Citations
Gene editing strategies to treat lysosomal disorders: The example of mucopolysaccharidoses	789
Editorial board members	405
Emerging antibiotic alternatives: From antimicrobial peptides to bacteriophage therapies	320
Genome-scale metabolic modelling in antimicrobial pharmacology: Present and future	319
MIDD in Japan– Implementations, challenges and opportunities	287
Leveraging the neurosurgical operating room for therapeutic development in NeuroOncology	279
Integrating microneedles and sensing strategies for diagnostic and monitoring applications: The state of the art	257
Nanoparticle-neutrophils interactions for autoimmune regulation	214
Penetration and translocation of functional inorganic nanomaterials into biological barriers	213
Drug delivery for metabolism targeted cancer immunotherapy	205
In vitro models of the interplay between glioblastoma and blood–brain barrier for stratifying drug efficacy	190
Models to study basic and applied aspects of lysosomal storage disorders	188
Long-acting inhaled medicines: Present and future	185
Liposomal formulations for treating lysosomal storage disorders	173
Polymer-based drug delivery systems under investigation for enzyme replacement and other therapies of lysosomal storage disorders	168
Emerging strategies to bypass transplant rejection via biomaterial-assisted immunoengineering: Insights from islets and beyond	164
Design, development and clinical translation of CriPec®-based core-crosslinked polymeric micelles	164
Deciphering albumin-directed drug delivery by imaging	158
Nanovaccines with cell-derived components for cancer immunotherapy	157
Tools for computational design and high-throughput screening of therapeutic enzymes	154
Luminescent quantum dots: Synthesis, optical properties, bioimaging and toxicity	150
Drug delivery strategies in maximizing anti-angiogenesis and anti-tumor immunity	149
Nanoparticle designs for delivery of nucleic acid therapeutics as brain cancer therapies	148
Cell membrane-coated nanoparticles for targeting carcinogenic bacteria	147
Opportunities and challenges in delivering biologics for Alzheimer’s disease by low-intensity ultrasound	145

Progress on the pathological tissue microenvironment barrier-modulated nanomedicine	144
Bacterially mediated drug delivery and therapeutics: Strategies and advancements	141
MicroRNAs and their delivery in diabetic fibrosis	137
Editorial Board	135
Recent advances in endocrine organoids for therapeutic application	135
Synthetic biology-guided design and biosynthesis of protein polymers for delivery	128
From cells to subcellular organelles: Next-generation cancer therapy based on peptide self-assembly	127
Protein encapsulation of nanocatalysts: A feasible approach to facilitate catalytic theranostics	127
Editorial/Preface	123
Targeting microbiome, drug metabolism, and drug delivery in oncology	121
Emerging Voices in Drug Delivery – Harnessing and Modulating Complex Biological Systems (Issue 2)	120
Biopharmaceutical drug delivery and phototherapy using protein crystals	119
Novel strategies for modulating the gut microbiome for cancer therapy	118
Hydrogen sulfide in cancer therapy: Intelligent delivery platforms and synergistic therapeutic paradigms	118
Biomarker and therapeutic potential of peripheral extracellular vesicles in Alzheimer’s disease	117
iPSC-derived T cells and macrophages: Manufacturing and next-generation application approaches	116
Activatable dual-functional molecular agents for imaging-guided cancer therapy	116
RNA binding proteins (RBPs) and their role in DNA damage and radiation response in cancer	115
Nanoparticles-mediated ion channels manipulation: From their membrane interactions to bioapplications	114
Exosome- and extracellular vesicle-based approaches for the treatment of lysosomal storage disorders	113
Strategies to develop polymeric microneedles for controlled drug release	112
Ultrasonic particles: An approach for targeted gene delivery	112
In situ cellular hitchhiking of nanoparticles for drug delivery	109
Pulmonary delivery nanomedicines towards circumventing physiological barriers: Strategies and characterization approaches	108
Drug delivery using gold nanoparticles	105
Activatable fluorescent probes for real-time imaging-guided tumor therapy	104
Oral delivery of therapeutic peptides and proteins: Technology landscape of lipid-based nanocarriers	103
Solid implantable devices for sustained drug delivery	102
In-vitro 3D modelling for charged particle therapy – Uncertainties and opportunities	101
3D printing of drug delivery systems enhanced with micro/nano-technology	101
Technological and translational challenges for extracellular vesicle in therapy and diagnosis	100
Lysosomal therapies and drug delivery strategies: An overview	100
Micro-patterned cell populations as advanced pharmaceutical drugs with precise functional control	99
Convection-enhanced delivery for brain malignancies: Technical parameters, formulation strategies and clinical perspectives	98
Engineering bacterial membrane nanovesicles for improved therapies in infectious diseases and cancer	98
Nanobodies: Robust miniprotein binders in biomedicine	97
Soft nano and microstructures for the photomodulation of cellular signaling and behavior	96
Emerging drug delivery systems with traditional routes – A roadmap to chronic inflammatory diseases	96
Miniaturized therapeutic systems for ultrasound-modulated drug delivery to the central and peripheral nervous system	94
Light sheet fluorescence microscopy for monitoring drug delivery: Unlocking the developmental phases of embryos	91
Fit and forget: The future of dental implant therapy via nanotechnology	91
Model-informed precision dosing: State of the art and future perspectives	90
Lipid nanoparticles for targeted delivery of anticancer therapeutics: Recent advances in development of siRNA and lipoprotein-mimicking nanocarriers	90
Unignored intracellular journey and biomedical applications of extracellular vesicles	90
Antibody-drug conjugates as multimodal therapies against hard-to-treat cancers	89
Nanosensitizer-mediated unique dynamic therapy tactics for effective inhibition of deep tumors	89
Overcoming therapy resistance in pancreatic cancer: challenges and emerging strategies	89
The extracellular matrix of hematopoietic stem cell niches	89
Novel drug delivery systems for the management of dry eye	89
To PEGylate or not to PEGylate: Immunological properties of nanomedicine’s most popular component, polyethylene glycol and its alternatives	89

Engineering complexity in human tissue models of cancer	88
Tumor microenvironment subtyping in pancreatic ductal adenocarcinoma: New avenues for personalized therapeutic strategies	87
Tumour extravasation of nanomedicine: The EPR and alternative pathways	87
Advances in photoactivated carbon-based nanostructured materials for targeted cancer therapy	87
Hurdles in translating science from lab to market in delivery systems for Cosmetics: An industrial perspective	86
Corrigendum to “Editorial: Advanced strategies to bridge the gap between inflammation and tissue regeneration” [Adv. Drug Deliv. Rev. 209 (2024) 115328]	85
Oral nanomedicine biointeractions in the gastrointestinal tract in health and disease	84
Preface: Image-assisted organoid research and application	84
Responsive nanomedicines enhanced by or enhancing physical modalities to treat solid cancer tumors: Preclinical and clinical evidence of safety and efficacy	84
Editorial Board	84
Editorial board members	83
Nanomedicine from amphiphilized prodrugs: Concept and clinical translation	83
Gelatin-integrated carbon nanomaterials in nanomedicine: From biosensing and bioprinting to tissue engineering and other biomedical applications	83
Editorial board members	82
Editorial board members	81
Corrigendum to ‘Cell-penetrating peptides in protein mimicry and cancer therapeutics’ [Advanced Drug Delivery Reviews, 180 (2022), 114044]	81
Design principles for construction of DNA-based nanostructures	81
MicroRNA-targeting nanomedicines for the treatment of intervertebral disc degeneration	80
Optical clearing of tissues: Issues of antimicrobial phototherapy and drug delivery	80
Modulating tumor physical microenvironment for fueling CAR-T cell therapy	79
Trends and patterns in cancer nanotechnology research: A survey of NCI's caNanoLab and nanotechnology characterization laboratory	79
Listening to drug delivery and responses via photoacoustic imaging	79
Beyond the adverse effects of the systemic route: Exploiting nanocarriers for the topical treatment of skin cancers	79
Nanoparticles for local delivery of siRNA in lung therapy	79
Aptamer-based targeted drug delivery and disease therapy in preclinical and clinical applications	78
Molecularly targeted nanomedicine enabled by inorganic nanoparticles for atherosclerosis diagnosis and treatment	77
Recent progress in upconversion nanomaterials for emerging optical biological applications	77
Lipid nanoparticles strategies to modify pharmacokinetics of central nervous system targeting drugs: Crossing or circumventing the blood–brain barrier (BBB) to manage neurological disorders	76
Harnessing inhaled nanoparticles to overcome the pulmonary barrier for respiratory disease therapy	76
Design of disintegrable nanoassemblies to release multiple small-sized nanoparticles	76
Nanoparticle-based immunotherapeutics: From the properties of nanocores to the differential effects of administration routes	76
Recent advances in intelligent oxygen delivery systems for tissue regeneration	75
Reversibility and therapeutic development for neurodevelopmental disorders, insights from genetic animal models	75
Editorial: Subcellular organelle-targeting of nanomaterials for enhancing therapeutic effectiveness	75
Lysosomal-mediated drug release and activation for cancer therapy and immunotherapy	75
Investigating the restriction-modification barrier to DNA delivery in human gut probiotic bacteria for streamlined genetic tool development	74
Drug delivery, development, and technological aspects for peripheral drug eluting stents	74
Blood-brain barrier delivery for lysosomal storage disorders with IgG-lysosomal enzyme fusion proteins	73
Microbial heterogeneity-mediated treatment evasion and the potential for engineered live biotherapeutic products	73
Spectral computed tomography with inorganic nanomaterials: State-of-the-art	73
Patient-Derived 3D-Bioprinted Models of Pancreatic Cancer: Toward Personalized Therapy and Overcoming Tumor Microenvironment Challenges	72
Additive manufacturing in spatial patterning for spinal cord injury treatment	71
Omics approaches for the assessment of biological responses to nanoparticles	71
Progress of engineered bacteria for tumor therapy	71
Clinical translation of advanced colonic drug delivery technologies	71
Storming the gate: New approaches for targeting the dynamic tight junction for improved drug delivery	70
mRNA delivery systems for cancer immunotherapy: Lipid nanoparticles and beyond	70
Of devices and drugs – Ingestible bots for diagnosis and therapy	69
Intrathecal delivery and its applications in leptomeningeal disease	69
Editorial Board	69
Corrigendum to “Advanced theragnostics for the central nervous system (CNS) and neurological disorders using functional inorganic nanomaterials” [Adv. Drug Delivery Rev. 192 (2023) 114636]	69
Towards controlled drug delivery in brain tumors with microbubble-enhanced focused ultrasound	68
Nitric oxide-modulating biomaterials for therapeutic Immunoengineering	67
Microbiota and plant-derived vesicles that serve as therapeutic agents and delivery carriers to regulate metabolic syndrome	67
Get out or die trying: Peptide- and protein-based endosomal escape of RNA therapeutics	67
3D extrusion bioprinting of microbial inks for biomedical applications	67
Delivery and kinetics of immersion optical clearing agents in tissues: Optical imaging from ex vivo to in vivo	66
Recent developments in lactose blend formulations for carrier-based dry powder inhalation	66
Steric stabilization of bioactive nanoparticles using elastin-like polypeptides	66
Nanoarchitectured two-dimensional layered double hydroxides-based nanocomposites for biomedical applications	65
Applications of pharmacometrics in drug development	65
Imaging drug delivery to the lungs: Methods and applications in oncology	65
Cell-penetrating peptides in protein mimicry and cancer therapeutics	64
Dynamic nano-assemblies based on two-dimensional inorganic nanoparticles: Construction and preclinical demonstration	64
Engineering of stimuli-responsive self-assembled biomimetic nanoparticles	64
Intranasal and inhaled delivery systems for targeting circadian dysfunction in neurodegenerative disorders, perspective and future outlook	64
Advances in Salmonella Typhimurium-based drug delivery system for cancer therapy	63
Local scaffold-assisted delivery of immunotherapeutic agents for improved cancer immunotherapy	62
The dynamic, motile and deformative properties of RNA nanoparticles facilitate the third milestone of drug development	62
The tendon microenvironment: Engineered in vitro models to study cellular crosstalk	61
Protein corona: Friend or foe? Co-opting serum proteins for nanoparticle delivery	61
The tumor EPR effect for cancer drug delivery: Current status, limitations, and alternatives	61
Special Issue (SI) on: Emerging pharmaceutical technologies (From advanced materials & formulations to new processes) for novel dosage development	60
Editorial board members	60
Pancreatic organoids as cancer avatars for true personalized medicine	60
Corrigendum to “Light sheet fluorescence microscopy for monitoring drug delivery: unlocking the developmental phases of embryos” [Adv Drug Del. Rev. 218 (2025) 115520]	60
Laser ablation: Heating up the anti-tumor response in the intracranial compartment	59
Revealing the clinical potential of high-resolution organoids	59
Nanomedicine for targeting brain Neurodegeneration: Critical barriers and circadian rhythm Considerations	59
Biosafety of mesoporous silica nanoparticles; towards clinical translation	58

Biomaterials releasing drug responsively to promote wound healing via regulation of pathological microenvironment	58
Delivery of synthetic mRNAs for tissue regeneration	58
Advancements of in vitro transcribed mRNA (IVT mRNA) to enable translation into the clinics	58
Sustained delivery approaches to improving adaptive immune responses	57
Microneedle-Mediated Vaccination: Innovation and Translation	57
Corrigendum to “Messenger RNA-based vaccines: Past, present, and future directions in the context of the COVID-19 pandemic” [Adv. Drug Delivery Rev. 179 (2021) 114000]	57
Merging data curation and machine learning to improve nanomedicines	56
Progress of tumor-resident intracellular bacteria for cancer therapy	56
Ocular therapies with biomacromolecules: From local injection to eyedrop and emerging noninvasive delivery strategies	56
Microbubble-assisted ultrasound for inner ear drug delivery	56
Towards artificial intelligence-enabled extracellular vesicle precision drug delivery	55
Editorial Board	55
Drug delivery across the blood-brain barrier for the treatment of pediatric brain tumors – An update	55
Next generation concepts in dermal delivery, theranostics, and preclinical testing	55
Integrated pharmacokinetic-pharmacodynamic and agent-based modelling in drug development: Current status and future perspectives	55
Theme issue: In vitro mucus models	54
Editorial board members	54
Editorial Board	54
Synthetic RNA-based post-transcriptional expression control methods and genetic circuits	53
Drugging the lymphatic system: An emerging opportunity for cancer immunotherapy	53
Targeted delivery methods for RNA interference are necessary to obtain a potential functional cure for HIV/AIDS	53
Critical review of nucleic acid nanotechnology to identify gaps and inform a strategy for accelerated clinical translation	53
Editorial board members	53
Cell-based relay delivery strategy in biomedical applications	53
Editorial board members	53
Biological and intracellular fates of drug nanocrystals through different delivery routes: Recent development enabled by bioimaging and PK modeling	52
The RNA-binding protein HuR in human cancer: A friend or foe?	52
Neurosurgery at the crossroads of immunology and nanotechnology. New reality in the COVID-19 pandemic	52
Photonic and magnetic materials for on-demand local drug delivery	52
Current issues in optical monitoring of drug delivery via hair follicles	52
Navigating the landscape of RNA delivery systems in cardiovascular disease therapeutics	52
Targeting bacterial metabolites in tumor for cancer therapy: An alternative approach for targeting tumor-associated bacteria	52
Long-acting parenteral drug delivery systems for the treatment of chronic diseases	51
Recent applications of three-dimensional bioprinting in drug discovery and development	51
Microfluidic fabrication of lipid nanoparticles for the delivery of nucleic acids	51
Biomedical engineering of two-dimensional MXenes	51
Precise subcellular targeting approaches for organelle-related disorders	50
From cells to organoids: The evolution of blood-brain barrier technology for modelling drug delivery in brain cancer	50
Fungal infections: Immune defense, immunotherapies and vaccines	50
Stealth and pseudo-stealth nanocarriers	50
The effects of protein corona on in vivo fate of nanocarriers	50
Transdermal drug delivery via microneedles to mediate wound microenvironment	49
Advances in modular control of CAR-T therapy with adapter-mediated CARs	49
Strategies to overcome/penetrate the BBB for systemic nanoparticle delivery to the brain/brain tumor	48
Strategies for overcoming protein and peptide instability in biodegradable drug delivery systems	48
Mitochondrial endogenous substance transport-inspired nanomaterials for mitochondria-targeted gene delivery	48
Translating a radiolabeled imaging agent to the clinic	47
Advances in mRNA therapeutics for cancer immunotherapy: From modification to delivery	47
Characterization of dry powder inhaler performance through experimental methods	47
Editorial Board	47
3D printing of pharmaceutical dosage forms: Recent advances and applications	47
Polymeric in situ forming depots for long-acting drug delivery systems	47
Effects of nanoparticle deformability on multiscale biotransport	47
Imaging and therapeutic targeting of the tumor immune microenvironment with biologics	47
Drug delivery strategies for local immunomodulation in transplantation: Bridging the translational gap	47